In contrast, despite the fact the PBRM1-deficient tumours grow more slowly than the parental B16 tumours, survival was further improved following Mps1 inhibitor treatment in mice bearing the PBRM1 KO derived tumours (Fig. 7j, k, and Supplementary Fig. 13g). This evidence concerns the gene PBRM1 and neoplasm.